NMR spectroscopy as a characterization tool enabling biologics formulation development

This review highlights recent advancements in using high resolution nuclear magnetic resonance (NMR) spectroscopy as a characterization tool to expedite biologics formulation development, meeting a current need in the biopharmaceutical industry. Conformational changes of protein therapeutics during formulation development can result in various protein-protein and protein-excipient interactions, which can lead to physical aggregation and/or chemical degradation. Innovative analytical techniques that allow studying protein integrity with high specificity during formulation development are urgently needed in order to assess protein formulation stability and mitigate product quality risks. Solution NMR spectroscopy is emerging as a powerful analytical tool for biophysical characterization of protein therapeutics. For instance, one-dimensional (1D) NMR has been employed in high sensitivity monitoring of monoclonal antibody (mAb) structural changes and protein-excipient interactions in parenteral formulations, demonstrating it as a potential tool for formulation screening. 2D NMR, such as ALSOFAST-[1H–13C]-HMQC experiments, on the other hand, offer superior capability to detect higher order structural (HOS) changes of mAbs in formulated solutions and their interactions with excipients. These determinations need to be achieved in actual formulations, where proteins of natural abundance are typically at low concentrations depending on the actual dose regimen. Studying proteins with natural abundance in the presence of hundredfold more concentrated excipients makes NMR studies of proteins in formulations extremely difficult considering the sample matrix interferences. Thus, successfully suppressing buffer signals while enhancing the protein signals of interest by optimizing the instrument specific parameters is critically important. Given the large size of typical mAbs, with a molecular weight (MW) ranging from 100 to 240 kDa, coupled with low protein concentrations, data collection becomes a demanding task in terms of NMR instrument time. As such, the biopharmaceutical industry is facing the common challenge of developing innovative NMR approaches to enhance signal detection (sensitivity and selectivity) and reduce experimental/instrument time. XL-ALSOFAST -[1H–13C]-HMQC was recently developed for tackling high MW proteins (up to 240 kDa) with much improved sensitivity and selectivity. We at BMS have implemented the XL-ALSOFAST experiment utilizing its high sensitivity and superior artifact suppression to successfully analyze formulations of several investigational proteins. In this manuscript we will discuss the general utility of this superior tool for studying therapeutic proteins across a range of molecular sizes and buffers. We envisage that this manuscript will serve as a primer to expand the role of NMR spectroscopy as a characterization tool supporting biologics formulation development.